Only one clinical trial using VDAs appears to be active: currently “Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer (MODULATE)”, which examines BNC105P and is organized by the Australasian Gastro-Intestinal Trials Group [76]. This evidence concerns the gene STAT3 and neoplasm.